MEDICINOVA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
MEDICINOVA, INC. (MNOV) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-02-15
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-12-31 was -$1.00.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-09-30 was $55.79K.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-06-30 was $136.60K.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-03-31 was $222.19K.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.41K, a 99.80% decline from fiscal 2021.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $700.00K, a 0.00% change from fiscal 2020.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $700.00K, a 86.54% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-15 | |||
| 2022-12-31 | $1.41K 10-K · filed 2024-02-15 | |||
| 2021-12-31 | $700.00K 10-K/A · filed 2023-03-28 | |||
| 2020-12-31 | $700.00K 10-K · filed 2022-02-16 | |||
| 2019-12-31 | $5.20M 10-K · filed 2021-02-19 | |||
| 2018-12-31 | $788.42K 10-K · filed 2020-02-13 | |||
| 2017-12-31 | $198.16K 10-K · filed 2019-02-13 | |||
| 2016-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $55.79K derived: sum of 2 quarters · filed 2019-02-13 | $192.39K derived: sum of 3 quarters · filed 2019-02-13 | $414.57K 10-K · filed 2019-02-13 |
| 2016-09-30 | $55.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-25 | $192.39K derived: sum of 2 quarters · filed 2016-10-25 | $414.57K 10-Q · filed 2016-10-25 | |
| 2016-06-30 | $136.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-26 | $358.78K 10-Q · filed 2016-07-26 | ||
| 2016-03-31 | $222.19K 10-Q · filed 2016-04-27 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-13 | |||
| 2014-12-31 | $4.74K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $8.48K derived: sum of 2 quarters · filed 2017-02-14 | $8.48K 10-K · filed 2017-02-14 | |
| 2014-09-30 | $3.75K 10-Q · filed 2015-10-29 | $3.75K 10-Q · filed 2015-10-29 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $64.00K 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | $64.00K 10-Q · filed 2013-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |